Full Press Release Details
ALX Oncology Announces New Data Demonstrating Evorpacept in Combination with Zanidatamab Generates Promising Antitumor Activity in Advanced Breast Cancer.
ALXO
ALX Oncology Announces New Data Demonstrating Evorpacept in Combination with Zanidatamab Generates Promising Antitumor Activity in Advanced Breast Cancer
Key Takeaway: ALX Oncology Announces New Data Demonstrating Evorpacept in Combination with Zanidatamab Generates Promising Antitumor Activity in Advanced Breast Cancer
Price reaction · baseline $1.72 (2024-12-09 close) · hit after-hours · 1 other ALXO headline(s) in the window, move may be shared
day 0 close
-8.1%
day 1
-12.2%
day 3 · peak
-15.7%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+102%
120-day peak, hindsight
Typical move
7.9%
average across 6 past catalysts
Cash runway
~25 mo
Minimal dilution risk
Lead asset
ALX2004
Phase 1 · NSCLC (Advanced Non-small Cell Lung Cancer)